N@N

Response Genetics Inc (NASDAQ:RGDX), Down By 8.53% ($0.11) From $1.290 After BUYINS.NET Report Predicted Weakness Before Earnin

^{Published on 2012-07-11 09:40:58 - WOPRAI}
 

July 11, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, June 28th 2012 stating that Response Genetics Inc (NASDAQ:RGDX) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=rgdx&id=288764

At the time this story was written, Response Genetics Inc (NASDAQ:RGDX) is Down By 8.53% ($0.11) From $1.290 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Response Genetics Inc (NASDAQ:RGDX) - Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suites for non-small cell lung cancer; ResponseDX: Colon test suites for colorectal cancer; and ResponseDX: Gastric test suites for gastric and gastroesophageal cancer. The companys Response DX test measures the RNA expression of ERCC1, TS, and RRM1 through reverse transcription polymerase chain reaction analysis from a patient's tumor tissue; and polymerase chain reaction analysis of DNA from the patient's sample to determine EGFR amplification, as well as BRAF, EGFR, and KRAS mutational status. It is also developing tests for other types of cancer that identify genetic profiles of tumors that recur after surgery. The company offers its products through its sales force to community based oncologists, hospitals, and physician offices. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Response Genetics Inc (NASDAQ:RGDX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net